Ellen Colman
YOU?
Author Swipe
View article: Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study
Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study Open
Long-term SZC use is associated with significant reductions in hyperkalemia-related hospitalizations or emergency department visits compared with short-term use among patients with heart failure or cardio/renal dysfunction.
View article: Hyperkalemia and Risk of CKD Progression: A Propensity Score–Matched Analysis
Hyperkalemia and Risk of CKD Progression: A Propensity Score–Matched Analysis Open
Key Points Hyperkalemia is a known complication of CKD; however, it is not known whether hyperkalemia directly contributes to CKD progression and risk of death. We found that patients with stages 3b/4 CKD and hyperkalemia had higher risk o…
View article: Economic burden of recurrent hyperkalemia in patients with chronic kidney disease
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease Open
Recurrent hyperkalemia in patients with stage 3/4 CKD was associated with higher all-cause HRU and medical costs compared with normokalemia (including in patients with Medicare coverage and RAASi use) and nonrecurrent hyperkalemia. Researc…
View article: #1481 Renin-angiotensin-aldosterone system inhibitor (RAASi) optimisation after initiating outpatient SZC therapy: the GALVANIZE RAASi real-world study
#1481 Renin-angiotensin-aldosterone system inhibitor (RAASi) optimisation after initiating outpatient SZC therapy: the GALVANIZE RAASi real-world study Open
Background and Aims Hyperkalaemia often occurs in patients with comorbidities that are treated with renin-angiotensin-aldosterone system inhibitors (RAASi), e.g., chronic kidney disease (CKD), heart failure or resistant hypertension. Howev…